Evidence map›Paper›PMID 33244099›Full record

ArticleScientific reports2020

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS

Eucharist H S Kun, Yvonne T M Tsang, Sophia Lin, Sophia Pan, Tejas Medapalli, Anais Malpica, JoAnne S Richards, David M Gershenson, Kwong-Kwok Wong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Eucharist H S KunDepartment of Gynecologic Oncology and Reproductive Medicine, Unit 1362, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Yvonne T M TsangDepartment of Gynecologic Oncology and Reproductive Medicine, Unit 1362, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Sophia LinDepartment of Gynecologic Oncology and Reproductive Medicine, Unit 1362, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Sophia PanDepartment of Gynecologic Oncology and Reproductive Medicine, Unit 1362, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Tejas MedapalliDepartment of Gynecologic Oncology and Reproductive Medicine, Unit 1362, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Anais MalpicaDepartments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
JoAnne S RichardsDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
David M GershensonDepartment of Gynecologic Oncology and Reproductive Medicine, Unit 1362, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Kwong-Kwok WongDepartment of Gynecologic Oncology and Reproductive Medicine, Unit 1362, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. kkwong@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Steroid Hormones Regulate Ovarian Cancer Progression and MetastasisR01CA181808 · NCI · BAYLOR COLLEGE OF MEDICINE · PI RICHARDS, JOANNE STEWART · 2014 to 2018
$1.7M
Functional Proteomics by Reverse Phase Protein Array in CancerR50CA221675 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, YILING · 2017 to 2021
$726k
A Novel Mouse Model for Uterine LeiomyomaR03CA219326 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WONG, KWONG KWOK · 2017 to 2018
$160k
Tissue Lysate Arrays for Molecular Screening (RMI)R03NS050840 · NINDS · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI LU, YILING · 2004 to 2004
$76k
NCI NIH HHS CA181808NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA181808NCI NIH HHS R03 CA219326NCI NIH HHS R50 CA221675NINDS NIH HHS R03 NS050840
6 · The paper itself

Abstract

How different KRAS variants impact tumor initiation and progression in vivo has not been thoroughly examined. We hypothesize that the ability of either KRAS

Indexed as

AnimalsFemaleGenital Neoplasms, FemaleGenotypeGranulosa Cell TumorHumansIntegrasesLeiomyomaLeiomyosarcomaMiceMice, Inbred C57BLMutationProto-Oncogene Proteins p21(ras)PTEN PhosphohydrolaseSignal TransductionCre recombinaseHras protein, mouseIntegrasesProto-Oncogene Proteins p21(ras)PTEN Phosphohydrolase

Identifiers

PMID33244099
PMCPMC7693266
OpenAlexW3110112774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.